Clinically-relevant research, reviews, clinical trials, and education focused on uterine leiomyosarcoma.
Comprehensive retrospective study informing diagnosis and management for uterine smooth muscle tumors of uncertain malignant potential.
Multidisciplinary sarcoma programs bring together surgical, medical, and radiation oncology expertise, with access to advanced imaging and clinical trials. For an overview of comprehensive sarcoma services — including evaluation, treatment planning, and second opinions — see the UCLA Health Sarcoma Center.
Dermawan JK et al. propose a clinically applicable genomic risk model for LMS, addressing heterogeneity and current gaps in risk tools.
Multi-cohort transcriptomic profiling identifies a subset of uterine LMS with a leiomyoma-like expression pattern associated with more favorable outcomes, suggesting utility for prognostic stratification and biological insight.
Review of DNA damage response, macrophage‑rich microenvironment, PI3K/mTOR, epigenetic regulators, and telomere biology in LMS.
Q: Studies on Letrozole — suitability for stage I/II vs advanced (III/IV)?
A: Best studied in metastatic setting; benefit variable; some patients may benefit anecdotally.
Imported exactly as provided to ensure every original item appears. Collapsed by default for readability.
Q: Studies on Letrozole – debate on whether it is best for Stage 1,2 Ulms instead of advanced states 3, 4:
A: “ Letrozole has been best studied (though small studies) in the metastatic setting. Here is a link to a publication from the DFCI group: https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.28476
It’s really not clear how much benefit these drugs have, but anecdotally patients can benefit.”
The primary literature is in metastatic disease ( stage 4) – the only trial which attempted to answer the question in early stage disease was closed due to poor accrual.
Some of the literature in the advanced setting is below.
Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma — https://pubmed.ncbi.nlm.nih.gov/35660331/
Novel Therapeutic Strategies targeting UCP2 in uLMS:
https://www.sciencedirect.com/science/article/pii/S104366182300049X?via%3Dihub
Overlap of Suspicious and Non-suspicious features in the Ultrasound Evaluation of Leiomyosarcoma – a Single-Center Experience
https://www.mdpi.com/2075-4418/13/3/543
Uterine LMS Staging Chart and comprehensive study
Important Video presentation on Uterine LMS research progress updates provided by Dr. Matthew Ingham, Columbia University Medical Center, on uterine sarcomas at the American Society of Clinical Oncology (ASCO)
Dr. Ingham is an esteemed member of the NLMSF‑SPAGN International LMS Research Roundtable and on the Executive Committee of the NLMSF.His presentation to the NLMSF Patient – Caregiver Advocacy Roundtable is here: https://youtu.be/mY2q7q5VOlAClinical Trial on Uterine LMS (last updated Aug 24, 2022):A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma — PI: Mathew Ingham, MD — NCT03880019Additionally, Dr. Gary Schwartz presented to the NLMSF Patient‑Caregiver Advocacy Roundtable:Dr. Gary Schwartz discussed the large clinical trial going into Phase III for uterine LMS clinical trial update: OncLive articleRecorded presentation: https://youtu.be/62gyn3nt6Z8
Stages I and II: Standard surgery is hysterectomy with BSO; lymph node evaluation as indicated. Adjuvant radiation may reduce local recurrence; chemo is considered in higher‑risk cases.
Stage III: Debulking/definitive surgery followed by radiation ± chemo depending on risk of recurrence.
Stage IV: IVA may be operable; otherwise radiation/chemo or both. IVB managed with systemic therapy; targeted therapy when appropriate.
See ACS for details: Surgery, Radiation therapy, Chemotherapy, Targeted therapy.
